ATS View
한국어

Kyung Nam Pharm KRX:053950KOSDAQ

경남제약 · Korean news coverage and regulatory filings, organized.

한국어
Articles, 24h0
Articles, 7 days12
DART filings, 7 days0
Articles tracked41since Sep 11

In Q2 2026, Kyung Nam Pharm reported revenue of ₩17.8bn, up 26.9% year on year, and an operating loss of ₩212m. Kyung Nam Pharm (경남제약) appeared in 12 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 12 articles.

Kyung Nam Pharm quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩17.8bn+26.9%−₩212m
margin −1.2%		−₩3.4bn
Q1 2026₩16.1bn+23.2%₩377m
margin 2.3%		−₩858m
Q4 2025 derived₩14.7bn-9.0%₩66m
margin 0.5%		−₩5.3bn
Q3 2025₩14.2bn-1.2%−₩1.1bn
margin −7.5%		−₩4.7bn
Q2 2025₩14.0bn-8.4%−₩839m
margin −6.0%		₩2.5bn
Q1 2025₩13.1bn-26.0%₩106m
margin 0.8%		−₩1.6bn
Q4 2024 derived₩16.1bn+3.2%₩273m
margin 1.7%		−₩2.0bn
Q3 2024₩14.3bn+2.4%−₩202m
margin −1.4%		−₩4.2bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

Kyung Nam Pharm top stories 2 weeks, by number of outlets

  1. 1
    경남제약, 신규 자금조달 방안 검토
    4 outlets · 4 articlesFirst report Oct 26 09:39 뉴시스경제
  2. 2
    경남제약, 유상증자 철회에 사업계획 조정…대체 자금조달 검토
    2 outlets · 2 articlesFirst report Oct 26 09:35 메디컬투데이
  3. 3
    경남제약, 유증 철회 후 자금조달 재검토…신제품 일정 조정
    2 outlets · 2 articlesFirst report Oct 26 09:41 파이낸셜뉴스
  4. 4
    경남제약, 유상증자 철회에 신제품·마케팅 계획 조정
    1 outlets · 1 articlesFirst report Oct 26 09:45 메디파나뉴스
  5. 5
    경남제약, 유상증자 철회 후 대체 자금줄 모색
    1 outlets · 1 articlesFirst report Oct 26 10:53 머니투데이
  6. 6
    경남제약, 유상증자 철회 후 플랜B 모색…운영자금부터 챙긴다
    1 outlets · 1 articlesFirst report Oct 26 15:54 한스경제

Latest Kyung Nam Pharm news Korean headlines